Denali Therapeutics Stock Quote DNLI - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

22.39

Bid

22.37

Ask

22.45

Volume

97,641

22.38 Day's Range 23.23

14.56 52 Week Range 33.33

Market Cap

3.222B

Previous Close

23.31

Open

22.96

Last Trade

22.41

Last Trade Time

10:44:25

Financial Volume

$ 2,220,429

VWAP

22.7407

Average Volume (3m)

956,821

Shares Outstanding

143,921,624

Dividend Yield

PE Ratio

-22.71

Earnings Per Share (EPS)

-1.01

Revenue

330.53M

Net Profit

-145.22M

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates ... Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.denalitherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

Denali Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DNLI. The last closing price for Denali Therapeutics was $23.31. Over the last year, Denali Therapeutics shares have traded in a share price range of $ 14.56 to $ 33.33.

Denali Therapeutics currently has 143,921,624 shares outstanding. The market capitalization of Denali Therapeutics is $3.35 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -22.71.

Form 8-K - Current report

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025Preparing for commercial...

Form 4 - Statement of changes in beneficial ownership of securities

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.84	3.89791183295	21.55	23.69	21.05	1044876	22.44793387	CS
4	1.68	8.11202317721	20.71	23.69	18.52	1018906	20.92713635	CS
12	-4.25	-15.9534534535	26.64	33.33	18.52	956821	23.64898734	CS
26	-0.99	-4.23438836612	23.38	33.33	18.52	903494	25.05572537	CS
52	4.55	25.5044843049	17.84	33.33	14.56	1047001	21.96259557	CS
156	-9.63	-30.0749531543	32.02	39.43	14.56	831568	24.72168484	CS
260	-1.01	-4.31623931624	23.4	93.94	12.39	740812	31.98937984	CS

DNLI - Frequently Asked Questions (FAQ)

What is the current Denali Therapeutics share price?

The current share price of Denali Therapeutics is $ 22.39

How many Denali Therapeutics shares are in issue?

Denali Therapeutics has 143,921,624 shares in issue

What is the market cap of Denali Therapeutics?

The market capitalisation of Denali Therapeutics is USD 3.35B

What is the 1 year trading range for Denali Therapeutics share price?

Denali Therapeutics has traded in the range of $ 14.56 to $ 33.33 during the past year

What is the PE ratio of Denali Therapeutics?

The price to earnings ratio of Denali Therapeutics is -22.71

What is the cash to sales ratio of Denali Therapeutics?

The cash to sales ratio of Denali Therapeutics is 9.98

What is the reporting currency for Denali Therapeutics?

Denali Therapeutics reports financial results in USD

What is the latest annual turnover for Denali Therapeutics?

The latest annual turnover of Denali Therapeutics is USD 330.53M

What is the latest annual profit for Denali Therapeutics?

The latest annual profit of Denali Therapeutics is USD -145.22M

What is the registered address of Denali Therapeutics?

The registered address for Denali Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Denali Therapeutics website address?

The website address for Denali Therapeutics is www.denalitherapeutics.com

Which industry sector does Denali Therapeutics operate in?

Denali Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DGNXDiginex Ltd	$ 17.23 (129.73%)	6.65M
NITON2OFF Inc	$ 1.42 (76.40%)	85.87M
HEPAHepion Pharmaceuticals Inc	$ 0.18985 (40.63%)	222.56M
DWTXDogwood Therapeutics Inc	$ 3.90 (39.29%)	1.17M
SPCBSuperCom Ltd	$ 17.359 (31.11%)	3.94M
ICONIcon Energy Corporation	$ 0.51 (-61.07%)	7.43M
JUNSJupiter Neurosciences Inc	$ 1.6606 (-53.61%)	5.06M
WHLRLWheeler Real Estate Investment Trust Inc	$ 99.76 (-31.44%)	12
SGLYSingularity Future Technology Ltd	$ 2.6192 (-29.21%)	577.25k
HAOHaoxi Health Technology Ltd	$ 0.1032 (-23.33%)	3.8M
HEPAHepion Pharmaceuticals Inc	$ 0.1899 (40.67%)	222.57M
NITON2OFF Inc	$ 1.4093 (75.07%)	85.93M
TNXPTonix Pharmaceuticals Holding Corporation	$ 0.3536 (10.85%)	77.9M
RGTIRigetti Computing Inc	$ 14.16 (1.80%)	63.82M
KOPNKopin Corporation	$ 1.78 (21.09%)	61.85M